EPG Online Twitter
EPG Online Blog
Disease Knowledge
Drug Updates
Cancer patients receiving drugs to lower the risk of anaemia may be...
Published Tuesday 01 December 2009
Chemotherapy can result in insomnia
Insomnia occurs in approximately three-quarters of cancer patients who have undergone chemotherapy....
Published Tuesday 01 December 2009
Osteoarthritis risk increased by high exercise levels
Men and women in middle age who exercise on a regular basis...
Published Monday 30 November 2009
Cancer genome changes increase cervical cancer relapse risk
Patients with cervical cancer are three to four times more likely to...
Published Sunday 29 November 2009
Number of Americans with diabetes expected to double by 2034
The number of people developing diabetes in the US is expected to...
Published Sunday 29 November 2009
H1N1 virus appears to increase asthma risk in children
Asthma is a significant risk factor in children who have contracted the...
Published Sunday 29 November 2009
New treatment could prevent thrombosis in PAD patients
Thrombosis is a common side effect in patients undergoing bypass surgery for...
Published Sunday 29 November 2009
Brazilian mint shown to combat pain
Patients experiencing chronic pain may benefit from Hyptis crenata, also known as...
Published Wednesday 25 November 2009
Chronic pain a risk factor for falls
Individuals experiencing chronic pain may be more likely to experience a fall...
Published Wednesday 25 November 2009
Fewer US hepatitis C patients receiving antiviral therapy
The number of hepatitis C (HCV) patients receiving antiviral therapy in the...
Published Tuesday 24 November 2009
Discovery could lead to improved non-Hodgkin's lymphoma treatment
Researchers in the US have discovered a new molecular mechanism which could...
Published Monday 23 November 2009
LDL cholesterol levels on the decline in the US
The number of adults with high levels of LDLcholesterol in the US...
Published Saturday 21 November 2009
Erectile dysfunction drug can benefit heart disease patients
A drug used for men with erectile dysfunction has been found to...
Published Thursday 19 November 2009
More Medical News
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
Antivirals.
Inosine pranobex - genital herpes
Each tablet contains 500mg Inosine Acedoben Dimepranol (INN, also known as inosine pranobex*) which is the p-acetamidobenzoic acid salt of N,N-dimethylamino-2-propanol [DIP.PAcBA] and ?-inosine in a 3:1 molar ratio. *British Approved Name (BAN) the non-proprietary designation
White to off-white tablets with a faint amine odour, engraved with a score-line on one side and 'DN' on the other. The score-line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Imunovir tablets are indicated in the management of: a) Mucocutaneous infections due to herpes simplex virus (type 1 and/or type II). b) Genital warts as adjunctive therapy to podophyllin or carbon dioxide laser. c) Subacute sclerosing panencephalitis (SSPE).
Adults:
Mucocutaneous herpes simplex: 1 g q.d.s. (4g daily), for 7 -14 days.
Genital warts: 1g t.d.s. (3g daily), for 14-28 days as adjunctive therapy to podophyllin or carbon dioxide laser.
Subacute sclerosing panencephalitis (SSPE): 50-100mg/kg daily, in divided does every 4 hours.
Children:
No information is available in children.
Elderly:
No dosage alterations are necessary in the elderly.
Not recommended.
There are no known contraindications to therapy with this drug.
As the inosine component of Imunovir is metabolised to uric acid, it should be used with caution in patients with renal impairment, a history of gout or hyperuricaemia
The only consistently observed drug-related side effect is a transient elevation (usually remaining within normal range) of urine and serum uric acid levels, which usually return to baseline values a few days after the end of treatment.
Side effects recorded in>1% of clinical studies of 3 months or longer and reported infrequently in postmarketing surveillance:
| Gastrointestinal | Nausea with or without vomiting, epigastric discomfort |
| Hepatic | Elevation of transaminases, alkaline phosphatase or blood urea nitrogen (BUN) level |
| Dermatological | Itching, skin rashes |
| Nervous system | Headaches, vertigo, fatigue or malaise |
| Other | Arthralgia |
| Gastrointestinal | Diarrhoea, constipation |
| Nervous system | Nervousness, drowsiness or insomnia |
| Genitourinary: | Polyuria (increased urine volume). |
Newport Pharmaceuticals Limited
(POM)
20 May 2009









